H.C. Wainwright initiated coverage of Senti Bio (SNTI) with a Buy rating and $12 price target The firm believes the company’s allogeneic CAR-NK cell therapy platform has the potential to treat several cancer types including hematologic malignancies and solid tumors. It views Senti as an “underappreciated CAR-NK player with a differentiated platform with a near-term catalyst” in Q4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.